APAlyssa A. Pullano

Alyssa A. Pullano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alyssa A. Pullano has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • Lyuba Bolkhovitinov

    HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA

    3 shared publications
  • Mark Connors

    National Institute of Allergy and Infectious Diseases

    3 shared publications
  • Andrew B. Ward

    Department of Integrative Structural and Computational Biology, The Scripps Research Institute

    2 shared publications
  • Andy Patamawenu

    HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA

    2 shared publications
  • Andy S. Tran

    Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, USA

    2 shared publications
  • Benjamin Leach

    HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA

    2 shared publications

Latest Publications

  • Open Access

    Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response

    by Kenta Matsuda, Mitra Harrison, Eleanor Wettstein, Jessica Pederson, Alyssa A. Pullano, Lyuba Bolkhovitinov, Breanna Kim, Isabel Steinberg, Trevor Griesman, Sarah Stuccio, et al.

    HIV-1 Env glycoprotein (Env) immunogenicity is limited in part by structural instability and extensive glycan shielding and is likely the greatest obstacle to an HIV-1 vaccine. Stabilized Env trimers can elicit serum neutralizing antibodies, but the response is short-lived. Here we use Newcastle Disease Virus-like particle (NDV-VLP) platform to present stabilized versions of HIV-1 Env at high valency and in the context of varied conformational stability, adjuvants, dose, and antigen persistence. Influenza virus hemagglutinin, or SARS-CoV2 Spike-bearing VLPs rapidly induce neutralizing antibodies, in contrast, they were not induced by those bearing Env. A replicating adenovirus type 4 expressing Env rapidly induces autologous neutralizing antibodies. However, durable neutralizing antibodies are induced only when multiple features of a replicating virus infection are combined, with the largest impact from dose and escalating dose. In summary, we show here immunogenicity of HIV-1 Env could be improved by reproducing features of virus infection.


  • Open Access

    Antigen Dose and Persistence Contribute to Induction of a Durable HIV-1-Specific Neutralizing Antibody Response

    by Mark Connors, Kenta Matsuda, Mitra Harrison, Eleanor Wettstein, Jessica Pederson, Alyssa Pullano, Lyuba Bolkhovitinov, Breanna Kim, Trevor Griesman, Sarah Stuccio, et al.

    The immunogenicity of HIV-1 Env glycoprotein (Env) is limited in part by its structural instability and extensive glycan shielding and is likely the greatest obstacle to an HIV-1 vaccine. Stabilized Env trimers can elicit serum neutralizing antibodies but often require many immunizations and the response is short-lived. To understand the parameters that confer a durable neutralizing antibody response, we used a Newcastle Disease Virus-like particle (NDV-VLP) platform to present stabilized versions of HIV-1 Env at high valency and varied the conformational stability, adjuvants, dose, and antigen persistence. Influenza virus hemagglutinin (HA), or SARS-CoV2 Spike (S)-bearing VLPs were used as controls. HA or S bearing VLPs rapidly induced neutralizing antibodies, whereas they were not induced by those bearing Env. A replicating adenovirus type 4 expressing Env rapidly induced autologous neutralizing antibodies, suggesting glycan shielding or the naïve B cell repertoire were not barriers. We then tested the parameters that might approximate a replicating virus infection. Only when multiple features of a virus infection were combined did we observe durable neutralizing antibodies, with the largest impact attributable to dose and escalating dose. Our results suggest that numerous features of a replicating virus infection, including stabilization, spike density, TLR stimulation, total dose, and persistence of antigen, can be combined to improve the immunogenicity of HIV-1 Env.

  • Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine

    by Kenta Matsuda, Jinghe Huang, Tongqing Zhou, Zizhang Sheng, Byong H. Kang, Elise Ishida, Trevor Griesman, Sarah Stuccio, Lyuba Bolkhovitinov, Teddy J. Wohlbold, et al.

    Ad4-H5 vaccine induces prolonged increases in H5-specific B cell frequency, antibody affinity, and somatic hypermutation.